16 hours Ago By ABMN Staff
Kymera Therapeutics, Inc. ( NASDAQ:KYMR – Get Free Report ) traded up 4.1% on Monday .
The company traded as high as $48.10 and last traded at $47.95.
57,179 shares were traded during mid-day trading, a decline of 91% from the average session volume of 626,700 shares. The stock had previously closed at $46.08.
Analyst Ratings Changes KYMR has been the topic of several recent analyst reports. Wells Fargo & Company increased their target price on Kymera Therapeutics from $30.00 to $38.
00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective for the company in a report on Monday, August 26th.
B. Riley boosted their target price on Kymera Therapeutics from $31.00 to $36.
00 and gave the stock a “neutral” rating in a research report on Tuesday, July 9th. Morgan Stanley raised their price target on shares of Kymera Therapeutics from $34.00 to $45.
00 and gave the company an “equal weight” rating in a report on Wednesday, August 14th. Finally, HC Wainwright reissued a “buy” rating and set a $46.00 price objective on shares of Kymera Therapeutics in a report on Monday, June 17th.
Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $48.
67. Read Our Latest Research Report on Kymera Therapeutics Kymera Therapeutics Stock Down 1.8 % Kymera Therapeutics ( NASDAQ:KYMR – Get Free Report ) last announced its earnings results on Wednesday, August 7th.
The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.
10. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.
27%. The company had revenue of $25.60 million for the quarter, compared to analysts’ expectations of $12.
55 million. During the same period last year, the firm earned ($0.67) EPS.
Kymera Therapeutics’s revenue for the quarter was up 55.2% compared to the same quarter last year. On average, analysts predict that Kymera Therapeutics, Inc.
will post -2.87 EPS for the current year. Insider Activity In related news, insider Jared Gollob sold 23,145 shares of the stock in a transaction that occurred on Tuesday, July 16th.
The shares were sold at an average price of $45.81, for a total value of $1,060,272.45.
Following the completion of the sale, the insider now directly owns 95,470 shares of the company’s stock, valued at approximately $4,373,480.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink .
In other news, Director Bruce Booth sold 453,960 shares of the company’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total value of $17,345,811.
60. Following the completion of the transaction, the director now owns 723,246 shares of the company’s stock, valued at $27,635,229.66.
The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink . Also, insider Jared Gollob sold 23,145 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $45.
81, for a total value of $1,060,272.45. Following the sale, the insider now directly owns 95,470 shares in the company, valued at approximately $4,373,480.
70. The disclosure for this sale can be found here . Insiders have sold a total of 495,605 shares of company stock valued at $19,303,364 in the last ninety days.
Corporate insiders own 15.82% of the company’s stock. Institutional Inflows and Outflows Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business.
Algert Global LLC lifted its holdings in shares of Kymera Therapeutics by 16.5% in the second quarter. Algert Global LLC now owns 32,706 shares of the company’s stock worth $976,000 after buying an additional 4,622 shares in the last quarter.
Driehaus Capital Management LLC bought a new stake in Kymera Therapeutics in the 2nd quarter valued at $6,669,000. Susquehanna Fundamental Investments LLC increased its holdings in Kymera Therapeutics by 7.4% in the 2nd quarter.
Susquehanna Fundamental Investments LLC now owns 76,818 shares of the company’s stock valued at $2,293,000 after acquiring an additional 5,325 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Kymera Therapeutics by 13.3% in the 2nd quarter.
The Manufacturers Life Insurance Company now owns 130,077 shares of the company’s stock worth $3,883,000 after purchasing an additional 15,320 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in shares of Kymera Therapeutics by 27.3% during the 2nd quarter.
Squarepoint Ops LLC now owns 108,563 shares of the company’s stock valued at $3,241,000 after purchasing an additional 23,312 shares during the last quarter. Kymera Therapeutics Company Profile ( Get Free Report ) Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Featured Articles Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
